1. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya. [Federal clinical recommendations for diagnostics and treatment of respiratory tuberculosis]. (written by Vasilyeva I.А., Аksenova V.А., Ergeshov А.E., Maryandyshev А.O., Samoylova А.G., Bagdasaryan T.R., Komissarova O.G., Lovacheva O.V., Perfiliev А.V., Karpina N.L., Kayukova S.I., Stakhanov V.А, Skornyakov S.N., Balasanyants G.S., Morozova T.I., Valiev R.Sh., Kazimirova N.E., Kazenny B.Ya., Klevno N.I., Baryshnikova L.А., Puzanov V.А., Popov S.А.). Moscow, Triada Publ., 2014, pp. 55.
2. Federalnye klinicheskie rekomendatsii po profilaktike, diagnostike i lecheniyu tuberkuleza u bolnykh VICH-infektsiey. [Federal clinical recommendations on prevention, diagnostics and treatment of tuberculous in HIV patients]. (written by Vasilyeva I.А., Voronin E.E., Pokrovskiy V.V., Аksenova V.А., Bagdasaryan T.R., Baryshnikova L.А., Valiev R.Sh., Viktorova I.B., Zagdyn Z.M., Zimina V.N., Kazimirova N.E., Karpina N.L., Kayukova S.I., Klevno N.I., Kononchuk O.N., Kravchenko А.V., Larionova E.E., Maryandyshev А.O., Mikhaylovskiy А.M., Morozova T.I., Okhtyarkina V.V., Panteleev А.M., Samoylova А.G., Sevastyanova E.V., Sinitsyn M.V., Skornyakov S.N., Stakhanov V.А., Chernousova L.N., Ergeshov А.E., Yurin O.G.). Moscow, 2016.
3. Alfarisi O., Alghamdi W.A., Al-Shaer M.H., Dooley K.E., Peloquin C.A. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert. Rev. Clin. Pharmacol., 2017, no. 10, pp. 1027-1036. doi: 10.1080/17512433.2017.1366311.Epub 2017 Aug 18.
4. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., Gordin F., Horsburgh C.R., Horton J., Khan A., Lahart C., Metchock B., Pachucki C., Stanton L., Vernon A., Villarino M.E., Wang Y.C., Weiner M., Weis S. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet, 2002, vol. 360 (9332), pp. 528-534.
5. Bock N.N., Sterling T.R., Hamilton C.D., Pachucki C., Wang Y.C., Conwell D.S., Mosher A., Samuels M., Vernon A. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Respir. Crit. Care Med., 2002, vol. 165, no. 11, pp. 1526-1530.